In our study, for both categories of baseline vision, the two treatment groups had comparable final BCVA and CMT, indicating similar effectiveness of anti-VEGF therapy, regardless of diabetes treatment modality or baseline vision. The gene discussed is VEGFA; the disease is diabetes mellitus.